This text is a result of machine translation.
Jiangsu Hengrui, Chinese Cancer Drugmaker Emerging from the Shadows
A flagship in the Chinese oncology market, Jiangsu Hengrui Medicine (600276:SH) was accused of corruption in sales. This was soon followed by good news – an approval of a Phase III clinical test. Will a bright future erase the black stain?
May 22, 2020 10:52 PM
Yingkang life: it is expected to lose 300 million yuan to 370 million yuan in 2021
Beijing Pilots The DRG External Payment Mode
DRG refers to the diagnosis-related group used to classify the patient and set up a system to ensure the care provided is necessary. The National Healthcare Security Administration will pay the hospital a predetermined amount according to a patient’s DRG.
Jul 16, 2022 12:12 AM
The coal sector fell sharply at the opening, and Shanghai Energy fell by the limit
New Normal, New Policies: A Focus on Healthcare in Two Sessions
The week-long Chinese virtual ‘Two Sessions’ meeting closed on May 28. The hovering pandemic has made the healthcare topic a highlight for the 2020 third session of the 13th National People’s Congress.
Jun 03, 2020 03:06 PM
Defining key tasks and accelerating the construction of new urbanization
Black Friday Kicks Off: How to Navigate the Latin American Market?
Nov 20, 2024 10:36 AM
Exploring Uncharted Territories in the Middle East: The Innovators Going Global
Nov 19, 2024 03:20 PM
The Billion-Dollar European Caviar Business, Now Disrupted by China
Nov 08, 2024 01:52 PM